BioSpecifics Technologies (NASDAQ: BSTC) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare BioSpecifics Technologies to related businesses based on the strength of its dividends, institutional ownership, risk, earnings, analyst recommendations, profitability and valuation.

Risk & Volatility

BioSpecifics Technologies has a beta of 1.59, meaning that its stock price is 59% more volatile than the S&P 500. Comparatively, BioSpecifics Technologies’ competitors have a beta of 1.27, meaning that their average stock price is 27% more volatile than the S&P 500.


This table compares BioSpecifics Technologies and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioSpecifics Technologies 42.40% 19.11% 16.84%
BioSpecifics Technologies Competitors -5,411.14% -160.70% -35.75%

Analyst Recommendations

This is a summary of recent ratings and price targets for BioSpecifics Technologies and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioSpecifics Technologies 0 0 1 0 3.00
BioSpecifics Technologies Competitors 1175 3521 12062 248 2.67

BioSpecifics Technologies currently has a consensus price target of $65.00, indicating a potential upside of 47.16%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 31.98%. Given BioSpecifics Technologies’ stronger consensus rating and higher probable upside, analysts clearly believe BioSpecifics Technologies is more favorable than its competitors.

Earnings and Valuation

This table compares BioSpecifics Technologies and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
BioSpecifics Technologies $26.25 million $11.37 million 27.78
BioSpecifics Technologies Competitors $290.27 million $35.99 million 72.07

BioSpecifics Technologies’ competitors have higher revenue and earnings than BioSpecifics Technologies. BioSpecifics Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

55.0% of BioSpecifics Technologies shares are owned by institutional investors. Comparatively, 49.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 21.5% of BioSpecifics Technologies shares are owned by insiders. Comparatively, 16.8% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


BioSpecifics Technologies beats its competitors on 9 of the 13 factors compared.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development. Injectable collagenase clostridium histolyticum is marketed as XIAFLEX (or Xiapex in Europe). The two marketed indications involving its injectable collagenase are Dupuytren’s contracture and Peyronie’s disease. The other clinical indications for which its collagenase injection has been tested include keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. The Company is evaluating its options for development of additional indications using collagenase.

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with's FREE daily email newsletter.